Xencor, Inc.

NasdaqGM:XNCR Stock Report

Market Cap: US$1.1b

Xencor Management

Management criteria checks 3/4

Xencor's CEO is Bassil Dahiyat, appointed in Aug 1997, has a tenure of 28.25 years. total yearly compensation is $6.81M, comprised of 10.6% salary and 89.4% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $4.71M. The average tenure of the management team and the board of directors is 3.3 years and 8.3 years respectively.

Key information

Bassil Dahiyat

Chief executive officer

US$6.8m

Total compensation

CEO salary percentage10.59%
CEO tenure28.3yrs
CEO ownership0.4%
Management average tenure3.3yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 31% Share Price Rise

Sep 25
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 31% Share Price Rise

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

Sep 19

Health Check: How Prudently Does Xencor (NASDAQ:XNCR) Use Debt?

Sep 18
Health Check: How Prudently Does Xencor (NASDAQ:XNCR) Use Debt?

Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking

Aug 06
Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking
User avatar

IBD Biologics And TL1A Programs Will Forge New Paths

Differentiated drug design and flexible development platform position Xencor for increased patient adoption, operational efficiency, and attractive long-term profitability.

Is Xencor (NASDAQ:XNCR) A Risky Investment?

Apr 26
Is Xencor (NASDAQ:XNCR) A Risky Investment?

Xencor, Inc. (NASDAQ:XNCR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Mar 30
Xencor, Inc. (NASDAQ:XNCR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27%

Feb 04
Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27%

Xencor: Substantial Promise, Slow Progress

Jan 30

Is Xencor (NASDAQ:XNCR) Using Too Much Debt?

Dec 31
Is Xencor (NASDAQ:XNCR) Using Too Much Debt?

Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up

Dec 03
Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 10
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Sep 12

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Sep 12
Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Sep 06
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Jul 13
Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Jun 16
Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Mar 27
Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor: Standing Out With XmAb Technology

Feb 03

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Jan 05
Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Nov 13
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Nov 10
Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08
Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12
Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18
Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

CEO Compensation Analysis

How has Bassil Dahiyat's remuneration changed compared to Xencor's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$131m

Jun 30 2025n/an/a

-US$171m

Mar 31 2025n/an/a

-US$208m

Dec 31 2024US$7mUS$721k

-US$233m

Sep 30 2024n/an/a

-US$213m

Jun 30 2024n/an/a

-US$191m

Mar 31 2024n/an/a

-US$146m

Dec 31 2023US$8mUS$700k

-US$133m

Sep 30 2023n/an/a

-US$119m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$8mUS$670k

-US$55m

Sep 30 2022n/an/a

US$30m

Jun 30 2022n/an/a

US$22m

Mar 31 2022n/an/a

US$109m

Dec 31 2021US$5mUS$625k

US$83m

Sep 30 2021n/an/a

-US$4m

Jun 30 2021n/an/a

US$24m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$4mUS$600k

-US$69m

Sep 30 2020n/an/a

-US$83m

Jun 30 2020n/an/a

-US$80m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$4mUS$567k

US$27m

Sep 30 2019n/an/a

US$36m

Jun 30 2019n/an/a

US$49m

Mar 31 2019n/an/a

US$39m

Dec 31 2018US$4mUS$550k

-US$70m

Compensation vs Market: Bassil's total compensation ($USD6.81M) is above average for companies of similar size in the US market ($USD3.60M).

Compensation vs Earnings: Bassil's compensation has been consistent with company performance over the past year.

CEO

Bassil Dahiyat (55 yo)

28.3yrs
Tenure
US$6,811,829
Compensation

Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...

Leadership Team

NamePositionTenureCompensationOwnership
Bassil Dahiyat
Co-Founder28.3yrsUS$6.81m0.42%
$ 4.7m
Bart Cornelissen
Senior VP & CFO1.6yrsUS$3.86m0.016%
$ 175.2k
John Desjarlais
Executive VP of Research & Chief Scientific Officer11.3yrsUS$2.83m0.26%
$ 2.9m
Celia Eckert
Senior VP6.2yrsUS$1.97m0.041%
$ 458.1k
Charles Liles
Associate Director and Head of Corporate Communications & Investor Relationsno datano datano data
Jennifer Sandoz
Senior VIce President of Human Resources4.3yrsno datano data
Kirk Rosemark
Senior Vice President of Regulatory Affairs & Quality Assurance3.8yrsno datano data
Eric Kowack
Senior Vice President of Program Leadership & Alliance Management2.8yrsno datano data
Dane Leone
Executive VP & Chief Strategy Officer1.8yrsno datano data
Rod Humerickhouse
Senior Vice President of Clinical Development (Oncology)less than a yearno datano data
Mark Osterman
Senior Vice President of Clinical Development (Autoimmune)less than a yearno datano data
3.3yrs
Average Tenure
55yo
Average Age

Experienced Management: XNCR's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bassil Dahiyat
Co-Founder28.3yrsUS$6.81m0.42%
$ 4.7m
Todd Simpson
Independent Directorless than a yearno datano data
Richard Ranieri
Independent Director7.9yrsUS$340.40k0.0077%
$ 85.9k
Alan Montgomery
lead Independent Director10.7yrsUS$372.90k0.0097%
$ 108.2k
Kevin Gorman
Independent Director8.6yrsUS$332.90k0.0073%
$ 81.5k
Raymond Deshaies
Directorless than a yearno datano data
Jeffrey Ravetch
Member of Scientific Advisory Board16.4yrsno datano data
Ellen Feigal
Independent Director7yrsUS$338.40k0.0077%
$ 85.9k
Kurt Gustafson
Independent Director11.3yrsUS$336.90k0.0091%
$ 101.5k
Barbara Klencke
Independent Director2.2yrsUS$324.40k0%
$ 0
8.3yrs
Average Tenure
68yo
Average Age

Experienced Board: XNCR's board of directors are considered experienced (8.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/18 11:57
End of Day Share Price 2025/11/18 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xencor, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBarclays
Zhiqiang ShuBerenberg